Next Article in Journal
Previous Article in Journal
Int. J. Mol. Sci. 2012, 13(2), 2208-2218; doi:10.3390/ijms13022208
Article

A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor

1,2
, 1
, 1
, 1
, 1,3,* , 3,4,*  and 3
Received: 17 January 2012; in revised form: 14 February 2012 / Accepted: 15 February 2012 / Published: 17 February 2012
View Full-Text   |   Download PDF [330 KB, updated 19 June 2014; original version uploaded 19 June 2014]
Abstract: Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC.
Keywords: mitomycin C; latent membrane protein 1; antibody targeted therapy; nasopharyngeal carcinoma; apoptosis; VEGF mitomycin C; latent membrane protein 1; antibody targeted therapy; nasopharyngeal carcinoma; apoptosis; VEGF
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Mao, Y.; Zhang, D.-W.; Wen, J.; Cao, Q.; Chen, R.-J.; Zhu, J.; Feng, Z.-Q. A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor. Int. J. Mol. Sci. 2012, 13, 2208-2218.

AMA Style

Mao Y, Zhang D-W, Wen J, Cao Q, Chen R-J, Zhu J, Feng Z-Q. A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor. International Journal of Molecular Sciences. 2012; 13(2):2208-2218.

Chicago/Turabian Style

Mao, Yuan; Zhang, Da-Wei; Wen, Juan; Cao, Qing; Chen, Ren-Jie; Zhu, Jin; Feng, Zhen-Qing. 2012. "A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor." Int. J. Mol. Sci. 13, no. 2: 2208-2218.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert